Athira pharma completes enrollment of phase 2/3 lift-ad clinical trial of fosgonimeton in mild-to-moderate alzheimer's disease

Topline data from lift-ad on track for second half of 2024 previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton potential first-in-class approach focused on hgf modulation for treatment of neurodegenerative diseases bothell, wash., jan. 03, 2024 (globe newswire) --  athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced completion of enrollment in the phase 2/3 lift-ad clinical trial of fosgonimeton as a potential treatment for mild-to-moderate alzheimer's disease.
ATHA Ratings Summary
ATHA Quant Ranking